ESC 365 - Why do we need new therapies for patients with HFrEF?

HFA Premium Access

Why do we need new therapies for patients with HFrEF?

Session: Baroreflex activation therapy in Heart Failure with reduced Ejection Fraction (HFrEF): overcoming the limits of currently available therapies

Topic: Heart Failure with Reduced Ejection Fraction (HFrEF)

Speaker: Professor B. Merkely (Budapest, HU)

Sponsored by Charité Berlin

Event: Heart Failure 2018

Congress Presentation

Add to my library

About the speaker

Professor Bela Merkely

Semmelweis University Heart and Vascular Center, Budapest (Hungary)

15 presentations

3 followers

3 more presentations in this session

Welcome and introduction - Baroreflex activation therapy in Heart Failure with reduced Ejection Fraction (HFrEF): overcoming the limits of currently available therapies.

Speaker: Professor S. Anker (Berlin, DE) Professor G. Filippatos (Athens, GR)

Review of new approaches to the management of HFrEF.

Speaker: Doctor E. Gronda (Sesto S. Giovanni, IT)

The developing case for using baroreflex activation therapy in HFrEF.

Speaker: Professor J. Bauersachs (Hannover, DE)

Access the full session

Baroreflex activation therapy in Heart Failure with reduced Ejection Fraction (HFrEF): overcoming the limits of currently available therapies

Speakers: Professor B. Merkely, Professor S. Anker, Professor G. Filippatos, Doctor E. Gronda, Professor J. Bauersachs

About the event

Heart Failure 2018

26 May - 29 May 2018

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources